Stage III NSCLC: durvalumab extends median PFS by 11.2 mo

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Durvalumab (Imfinzi, AstraZeneca) offers better PFS and lower incidence of new lesions than placebo for patients with stage III, locally advanced, unresectable NSCLC that has not progressed following chemoradiotherapy.

Why this matters

  • About one-third of patients with NSCL...